Steven N Kalkanis, MD

Member of the Henry Ford Cancer Institute

Biographical Statement

Steven Kalkanis, M.D., CEO of the Henry Ford Medical Group (HFMG) and Senior Vice President and Chief Academic Officer of Henry Ford Health System, provides strategic leadership and direction over the 1,900-member HFMG physicians and researchers responsible for all aspects of clinical performance across 40 specialties. Dr. Kalkanis works to advance the health system’s academic mission including the development and growth of all research and medical education programs.

Dr. Kalkanis joined Henry Ford in 2004 as a board-certified neurosurgeon after completing neurosurgical residency training at the Harvard - Massachusetts General Hospital program. In May 2014, he was named chair of Henry Ford’s Department of Neurosurgery, which is nationally recognized for research and clinical excellence.

An internationally recognized brain tumor expert, Dr. Kalkanis serves as president of the Congress of Neurological Surgeons, the largest association of its kind and as a Director of the American Board of Neurological Surgery, the profession's highest honor.

Actively involved in clinical trials and research, Dr. Kalkanis leads a translational research laboratory investigating the molecular genetic differences between short- and long-term brain tumor survivors with the goal of refining future personalized medicine treatment protocols.

Titles

• CEO, Henry Ford Medical Group
• Senior Vice President and Chief Academic Officer, Henry Ford Health
• Professor & Chairman Emeritus, Department of Neurosurgery
• Mark L. Rosenblum Endowed Chair in Neurosurgery
• Founding Medical Director, Henry Ford Cancer Institute

As a member of the Hermelin Brain Tumor Center team, I specialize in the treatment of all brain tumors including clinical trials; intracranial neurosurgery, spinal cord tumors, adult cervical and lumbar spine disease, general neurosurgery and stereotactic neurosurgery.

Research Interests

• Brain cancer research
• Clinical trials and outcome studies for brain tumor patients
• Targeted cell-based therapy for the treatment of malignant gliomas
• Viral gene therapy and stem cell delivery for novel brain cancer therapies
• Survival-associated genetic studies for the development of personalized medicine protocols for brain tumor patients

Awards and Honors

• Michigan's Top Docs, Detroit Hour Magazine (2008 - 2020)
• Director, American Board of Neurological Surgery
• National Executive Committee member, Congress of Neurological Surgeons (CNS)
• National Executive Committee member, Joint Tumor Section Chair
• National Tumor Section Guidelines Committee member
• Lead Author of the national guidelines for the treatment of brain metastases
• Editor, Neurosurgery Journal
• National first-place research award recipient, American College of Surgeons
• National first-place research award recipient, CNS
• Director, American Board of Neurological Surgery
• Past Chair, American Association of Neurological Surgeons/CNS Section on Tumors
• Past President, CNS
• Past President, Michigan Association of Neurological Surgeons